Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 97 points (0.5%) at 17,727 as of Wednesday, July 29, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,089 issues advancing vs. 896 declining with 165 unchanged.

The Drugs industry currently sits down 1.0% versus the S&P 500, which is up 0.5%. Top gainers within the industry include

Gilead

(

GILD

), up 3.2%,

Pfizer

(

PFE

), up 0.9% and

Johnson & Johnson

(

JNJ

), up 0.9%. On the negative front, top decliners within the industry include

Medivation

(

MDVN

), down 12.9%,

Incyte

(

INCY

), down 3.1%,

Biomarin Pharmaceutical

(

BMRN

), down 2.0%,

Regeneron Pharmaceuticals

(

REGN

), down 1.5% and

Teva Pharmaceutical Industries

(

TEVA

), down 0.8%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3.

Novartis

(

NVS

) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novartis is up $0.97 (0.9%) to $103.76 on average volume. Thus far, 765,242 shares of Novartis exchanged hands as compared to its average daily volume of 1.6 million shares. The stock has ranged in price between $103.48-$103.91 after having opened the day at $103.59 as compared to the previous trading day's close of $102.79.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. Novartis has a market cap of $245.2 billion and is part of the health care sector. Shares are up 10.9% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts who rate Novartis a buy, 1 analyst rates it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Novartis

as a

buy

. The company's strengths can be seen in multiple areas, such as its reasonable valuation levels, solid stock price performance, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Novartis Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

GlaxoSmithKline

(

GSK

) is up $1.11 (2.7%) to $42.82 on heavy volume. Thus far, 5.9 million shares of GlaxoSmithKline exchanged hands as compared to its average daily volume of 4.0 million shares. The stock has ranged in price between $42.69-$43.07 after having opened the day at $42.90 as compared to the previous trading day's close of $41.71.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. GlaxoSmithKline has a market cap of $100.5 billion and is part of the health care sector. Shares are down 2.4% year-to-date as of the close of trading on Tuesday. Currently there are 2 analysts who rate GlaxoSmithKline a buy, 1 analyst rates it a sell, and 5 rate it a hold.

TheStreet Ratings rates

GlaxoSmithKline

as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, attractive valuation levels, expanding profit margins and compelling growth in net income. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

GlaxoSmithKline Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Merck

(

MRK

) is up $1.14 (2.0%) to $58.66 on average volume. Thus far, 5.7 million shares of Merck exchanged hands as compared to its average daily volume of 9.3 million shares. The stock has ranged in price between $57.64-$58.76 after having opened the day at $57.70 as compared to the previous trading day's close of $57.52.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Merck & Co., Inc. provides health care solutions worldwide. Merck has a market cap of $161.0 billion and is part of the health care sector. Shares are up 1.3% year-to-date as of the close of trading on Tuesday. Currently there are 6 analysts who rate Merck a buy, no analysts rate it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Merck

as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had sub par growth in net income. Get the full

Merck Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).